WO2010038905A1 - Bactérie appartenant au genre pantoea produisant un acide l-aspartique ou des métabolites dérivés de l'acide l-aspartique et procédé de production d'acide l-aspartique ou de métabolites dérivés de l'acide l-aspartique - Google Patents

Bactérie appartenant au genre pantoea produisant un acide l-aspartique ou des métabolites dérivés de l'acide l-aspartique et procédé de production d'acide l-aspartique ou de métabolites dérivés de l'acide l-aspartique Download PDF

Info

Publication number
WO2010038905A1
WO2010038905A1 PCT/JP2009/067449 JP2009067449W WO2010038905A1 WO 2010038905 A1 WO2010038905 A1 WO 2010038905A1 JP 2009067449 W JP2009067449 W JP 2009067449W WO 2010038905 A1 WO2010038905 A1 WO 2010038905A1
Authority
WO
WIPO (PCT)
Prior art keywords
aspartic acid
gene
bacterium
dehydrogenase
activity
Prior art date
Application number
PCT/JP2009/067449
Other languages
English (en)
Inventor
Olga Nikolaevna Mokhova
Tatyana Mikhailovna Kuvaeva
Lyubov Igorevna Golubeva
Aleksandra Viktorovna Kolokolova
Joanna Yosifovna Katashkina
Original Assignee
Ajinomoto Co.,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co.,Inc. filed Critical Ajinomoto Co.,Inc.
Publication of WO2010038905A1 publication Critical patent/WO2010038905A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/20—Aspartic acid; Asparagine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/12—Methionine; Cysteine; Cystine

Definitions

  • the present invention relates to the microbiological industry, and specifically to a method for producing an L-aspartic acid or L-aspartic acid-derived metabolites using a bacterium belongiung to the genus Pantoea which has been modified to have attenuated expression of genes coding for ⁇ -ketoglutarate dehydrogenase and citrate synthase, as well as enhanced expression of genes coding for phosphoenolpyruvate carboxylase and glutamate dehydrogenase, or glutamate synthase.
  • L-amino acids are industrially produced by fermentation methods utilizing strains of microorganisms obtained from natural sources, or mutants thereof. Typically, the microorganisms are modified to enhance production yields of L-amino acids.
  • L-aspartic acid is a useful metabolite having different applications (aspartame sweetener, biodegradable polymers, etc.).
  • aspartic acid is produced enzymatically from fumarate using aspartase.
  • fumarate can be obtained by chemical synthesis, as a product of oil distillation or from hydrocarbons in bacterial fermentation process.
  • the three-step production process includes the steps of 1) production of calcium-fumarate by fermentation of a bacterial strain; 2) conversion of the calcium- fumarate to diammonium fumarate by addition of ammonia, ammonium carbonate, or ammonia in combination with CO 2 ; 3) enzymatic conversion of the obtained diammonium fumarate to ammonium aspartate by aspartase. This process has been previously described (US patent 6,071,728).
  • L-aspartic acid is synthesized in the aspartate aminotransferase reaction. It's keto-precursor is oxaloacetate, the intermediate of TCA (tricarboxylic acid cycle and glyoxylate bypass, reviewed in Neidhardt, F. C. (Ed. in Chief), R. Curtiss III, J.L. Ingraham, E.C.C. Lin, K.B. Low, B. Magasanik, W.S. Reznikoff, M. Riley, M. Schaechter, and H.E. Umbarger (eds). 1996. Escherichia coli and Salmonella: Cellular and Molecular Biology. American Society for Microbiology); L-glutamic acid serves as a donor of amides in this reaction.
  • the carbon flux to oxaloacetate in E. coli grown on glucose can be increased by increasing phosphoenol pyrvate (PEP)-carboxylase activity, in particular, due to expressing feedback resistant PEP-carboxylase enzymes (European Patent EP072301 IBl) or by introducing heterologous pyruvate (Pyr) carboxylases (US Patent 6,455,284).
  • PEP phosphoenol pyrvate
  • inactivation of oxaloacetate or malate consuming enzymes such as PEP carboxykinase encoded by the pckA gene or malic enzymes encoded by the sfcA and maeB genes, is important for the production of aspartic acid-derived metabolites (WO2007/017710).
  • citrate synthase activity was established as a factor for increasing production of L-lysine, an aspartic acid-derived amino acid, by C. glutamicum (Ozaki H., Shiio J. Production of lysine by pyruvate kinase mutants of Brevibacteriumflavum. Agr. and Biol. Chem., Vol.47(7):1569-1576 (1983)).
  • aspects of the present invention include enhancing the productivity of L- aspartic acid-producing strains and providing a method for producing L-aspartic acid using these strains.
  • the present invention provides a bacterium belonging to the genus Pantoea having an increased ability to produce L-aspartic acid or L-aspartic acid-derived metabolite and a method for producing L-aspartic acid or L-aspartic acid-derived metabolite using the bacterium.
  • bacterium as described above, wherein said bacterium has been further modified to have attenuated expression of a gene coding for malate dehydrogenase. It is a further aspect of the present invention to provide the bacterium as described above, wherein said expression of the gene coding for ⁇ -ketoglutarate dehydrogenase, citrate synthase, aspartate ammonia-lyase (aspartase), pyruvate kinase, glucose dehydrogenase or malate dehydrogenase is attenuated by inactivating said gene in the chromosome of the bacterium.
  • L-aspartic acid-derived metabolite is selected from the group consisting of L-threonine, L-lysine, L-methionine, and L-homoserine.
  • L-aspartic acid-derived metabolite is selected from the group consisting of L-threonine, L-lysine, L-methionine, and L-homoserine.
  • Figure 1 shows the construction of the pMW-E ⁇ spC plasmid.
  • Figure 2 shows the construction of the pMIVK620S and pMIV-Ptac-pycA plasmids.
  • Figure 3 is a photograph which shows accumulation of by-products by the 3 ⁇ , 4 ⁇ (ApykA) and 5 ⁇ strains in test-tube cultivation.
  • Figure 4 shows growth curves of ⁇ pgi ⁇ zwf, ⁇ pgi ⁇ gcd, ⁇ zwf ⁇ gcd and ⁇ pgi ⁇ zwf ⁇ gcd strains in glucose minimal medium
  • Figure 5 shows construction of the RSFPlac-pzwf and RSFPlac-pgnd plasmids.
  • Figure 6 shows construction of the RSFPlaclacI plasmid vector.
  • Figure 7 shows construction of the pMW-intxis-cat plasmid vector
  • Figure 8 shows construction of the phMIV-1 helper plasmid.
  • a bacterium belonging to the genus Pantoea means that the bacterium is classified as the genus Pantoea according to the classification known to a person skilled in the art of microbiology.
  • Some species of Enterobacter agglomerans were recently re-classified into Pantoea agglomerans, Pantoea ananatis, Pantoea stewartii or the like, based on a nucleotide sequence analysis of the 16S rRNA, etc. (International Journal of Systematic Bacteriology, July 1989, 39(3).p.337-345).
  • Pantoea ananatis or Pantoea stewartii (International Journal of Systematic Bacteriology, Jan. 1993, 43(1), pp.162-173).
  • Typical strains of the Pantoea bacteria include, but are not limited to, Pantoea ananatis, Pantoea stewartii, Pantoea agglomerans, and Pantoea citrea. Specific examples include the following strains: Pantoea ananatis AJ 13355 (FERM BP-6614, European Patent Publication No. 0952221), Pantoea ananatis AJ13356 (FERM BP-6615, European Patent Publication No.
  • Pantoea ananatis AJ 13601 Pantoea ananatis AJ 13601
  • An exemplary ⁇ -Red resistant strain is Pantoea ananatis SCl 7(0) (VKPM B-9246, RU application 2006134574, WO2008/075483).
  • bacteria producing L-aspartic acid or L-aspartic acid-derived metabolite can refer to the abilities to produce L-aspartic acid and/or one or more L- aspartic acid-derived metabolites, and to cause accumulation of L-aspartic acid or L- aspartic acid-derived metabolite(s) in a medium or cells of the bacterium to such a degree that L-aspartic acid or L-aspartic acid-derived metabolite can be collected from the medium or cells when the bacterium is cultured in the medium.
  • the phrase "bacterium producing L-aspartic acid or L-aspartic acid-derived metabolite” can mean a bacterium which is able to cause accumulation of a target L-amino acid in the culture medium in an amount larger than the wild-type or parental strain, and can also mean that the microorganism is able to cause accumulation in the medium of an amount not less than 0.4 g/L, and in another example not less than 1.0 g/L of the target L-amino acid.
  • the ability to produce L-aspartic acid or L-aspartic acid-derived metabolites in the bacterium can be a native or inherent ability, or can be imparted by modifying the bacterium using mutagenesis or recombinant DNA techniques.
  • L-aspartic acid refers to an L-aspartic acid or to any salt thereof, and can be called aspartic acid.
  • the L-aspartic acid-derived metabolites include L- threonine, L-lysine, L-methionine, and L-homoserine.
  • the expression of the gene coding for aspartate ammonia-lyase can also be attenuated.
  • the activity of ⁇ -ketoglutarate dehydrogenase can mean catalyzing the conversion of 2-ketoglutarate into succinyl-CoA, and production of NADH and CO 2 in an irreversible reaction within the 2-oxoglutarate dehydrogenase complex [(SucA) i 2 ] [(SuCB) 24 ] [(Lpd) 2 ].
  • the nucleotide sequence of the sucA gene and the amino acid sequence of SucA protein from P. ananatis are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
  • nucleotide sequence of the git A gene and the amino acid sequence of GItA protein from P. ananatis are shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively.
  • the ppc gene from E. coli is known (nucleotides complementary to nucleotides in positions from 4,148,470 to 4,151,121; GenBank accession no. NC_000913.2; gi: 49175990).
  • the ppc gene is located between the yijP and the argE genes on the chromosome of E. coli K- 12.
  • the nucleotide sequence of the ppc gene and the amino acid sequence of Ppc encoded by the ppc gene from E. coli are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively.
  • pyruvate carboxylase (synonyms: Pyc, PycA) can mean catalyzing the following reaction:
  • pyruvate carboxylase from Sinorhizobium meliloti is resistant to feedback inhibition by L-aspartic acid (Dunn, M.F. et al, Cloning and characterization of the pyruvate carboxylase from Sinorhizobium meliloti Rm 10211, Arch. Microbiol., 176, 355-363 (2001)). Therefore, the pycA gene from S. meliloti was cloned and integrated into an L-aspartic acid producing P. ananatis strain. The nucleotide sequence of the pycA gene and the amino acid sequence of PycA encoded by the pycA gene from S.
  • GdhA glutamate dehydrogenase
  • the gdhA gene from E. coli is known (nucleotides in positions from 1,840,395 to 1,841,738; GenBank accession no. NC 000913.2; gi: 49175990).
  • the gdhA gene is located between the ynjH and the ynjl ORPs on the chromosome of E. coli K- 12.
  • the nucleotide sequence of the gdhA gene and the amino acid sequence of GdhA encoded by the gdhA gene from E. coli are shown in S ⁇ Q ID NO: 9 and S ⁇ Q ID NO: 10, respectively.
  • the activity of glutamate synthase can mean catalyzing the single-step conversion of L-glutamine and alpha-ketoglutarate into two molecules of L-glutamate:
  • the glutamate synthase from E. coli includes two subunits encoded by the gltB and gltD genes organized into one operon.
  • the gltB and gltD genes from E. coli are known (nucleotides in positions from 3,352,654 to 3,357,207 and 3,357,220 to 3,358,638, respectively; GenBank accession no. NC 000913.2; gi: 49175990).
  • the gltBD operon is located between the yhcC ORP and the gltF gene on the chromosome of E. coli K- 12.
  • the nucleotide sequences of the gltB and gltD genes and the amino acid sequences of GltB and GltD encoded by the gltB and gltD genes from E. coli are shown in S ⁇ Q ID NO: 11, S ⁇ Q ID NO: 12, S ⁇ Q ID NO: 13, and S ⁇ Q ID NO: 14, respectively.
  • aspartate ammonia-lyase can mean catalyzing the reversible conversion of L-aspartic acid to fumaric acid and ammonia:
  • the nucleotide sequence of the asp A gene and the amino acid sequence of AspA protein from P. ananatis are shown in S ⁇ Q ID NO: 15 and S ⁇ Q ID NO: 16, respectively.
  • P. ananatis has two isozymes of pyruvate kinase: PykA and PykF.
  • the nucleotide sequence of the pykA gene and the amino acid sequence of PykA protein from P. ananatis are shown in SEQ ID NO: 114 and SEQ ID NO: 115, respectively.
  • the nucleotide sequence of the pykF gene and the amino acid sequences of PykF protein from P. ananatis are shown in SEQ ID NO: 116 and SEQ ID NO: 117, respectively.
  • nucleotide sequence of the gcd gene and the amino acid sequence of the Gcd protein from P. ananatis are shown in SEQ ID NO: 17 and SEQ ID NO: 18, respectively.
  • nucleotide sequence of the mdh gene and the amino acid sequence of Mdh protein from P. ananatis are shown in SEQ ID NO: 19 and SEQ ID NO: 20, respectively.
  • bacterium has been modified to have attenuated expression of the gene can mean that the bacterium has been modified in such a way that the modified bacterium can contain a reduced amount of the protein encoded by the gene as compared with an unmodified bacterium, or is unable to synthesize the protein encoded by the gene.
  • the phrase "inactivation of the gene” can mean that the modified gene encodes a completely non-functional protein. It is also possible that the modified DNA region is unable to naturally express the gene due to a deletion of a part of the gene, shifting of the reading frame of the gene, introduction of missense/nonsense mutation(s), or modification of an adjacent region of the gene, including sequences controlling gene expression, such as a promoter, enhancer, attenuator, ribosome-binding site, etc..
  • sequences controlling gene expression such as a promoter, enhancer, attenuator, ribosome-binding site, etc.
  • the presence or absence of the sue A, git A, asp A, gcd, or mdh gene in the chromosome of a bacterium can be detected by well-known methods, including PCR, Southern blotting and the like.
  • the expression levels of the genes can be estimated by measuring the amount of mRNA transcribed from the genes using various known methods including Northern blotting, quantitative RT-PCR, and the like.
  • the amounts or molecular weights of the proteins coded by the genes can be measured by known methods including SDS-PAGE followed by an immunoblotting assay (Western blotting analysis), and the like.
  • Expression of the gene can be attenuated by introducing a mutation into the gene on the chromosome so that the intracellular amount of the protein encoded by the gene is decreased as compared to an unmodified strain.
  • a mutation can be the introduction of insertion of a drug-resistance gene, or the deletion of a part of the gene or the entire gene (Qiu, Z. and Goodman, M.F., J. Biol. Chem., 272, 8611-8617 (1997); Kwon, D. H. et al, J. Antimicrob. Chemother., 46, 793-796 (2000)).
  • Expression of the gene can also be attenuated by modifying an expression regulating sequence such as the promoter, the Shine-Dalgarno (SD) sequence, etc. (WO95/34672, Carrier, T. A. and Keasling, J.D., Biotechnol Prog 15, 58-64 (1999)).
  • SD Shine-Dalgarno
  • a mutant gene can be prepared, and the bacterium to be modified can be transformed with a DNA fragment containing the mutant gene. Then, the native gene on the chromosome can be replaced with the mutant gene by homologous recombination, and the resulting strain can be selected.
  • Such gene replacement by homologous recombination can be conducted by employing a linear DNA, which is known as "Red-driven integration" (Datsenko, K.A. and Wanner, B. L., Proc. Natl. Acad. Sci.
  • An exemplary strain is the Pantoea ananatis strain which has been modified to be resistant to the product of the ⁇ -Red genes. Examples include but are not limited to the Pantoea ananatis strain SC 17(0) (VKPM B-9246, RU application 2006134574, WO2008/075483). Furthermore, the incorporation of a site-specific mutation by gene substitution using homologous recombination such as set forth above can also be conducted with a plasmid lacking the ability to replicate in the host.
  • Expression of the gene can also be attenuated by insertion of a transposon or an IS factor into the coding region of the gene (U.S. Patent No. 5,175,107), or by conventional methods, such as mutagenesis with UV irradiation or nitrosoguanidine (N-methyl-N'-nitro-N-nitrosoguanidine).
  • Inactivation of the gene can also be performed by conventional methods, such as by mutagenesis with UV irradiation or nitrosoguanidine (N-methyl-N'-nitro-N- nitrosoguanidine), site-directed mutagenesis, gene disruption using homologous recombination, or/and insertion-deletion mutagenesis (Yu, D. et al., Proc. Natl. Acad. Sci. USA, 2000, 97:12: 5978-83 and Datsenko, K.A. and Wanner, B.L., Proc. Natl. Acad. Sci. USA, 2000, 97:12: 6640-45) also called "Red-driven integration".
  • variant proteins inactivation of genes, and other methods can be applied to other proteins, genes, and in the breeding of bacteria described below.
  • enhancing the expression of the gene means that the expression of the gene is higher than that of a non-modified strain, for example, a wild-type strain.
  • modifications include increasing the copy number of the target gene per cell, increasing the expression level of the gene, and so forth.
  • the quantity of the copy number of the target gene is measured, for example, by restricting the chromosomal DNA followed by Southern blotting using a probe based on the gene sequence, fluorescence in situ hybridization (FISH), and the like.
  • FISH fluorescence in situ hybridization
  • the level of gene expression can be measured by various known methods including Northern blotting, quantitative RT-PCR, and the like.
  • wild-type strains that can act as a control include, for example, Pantoea ananatis FERM BP-6614.
  • the ppc, pycA, gdhA, or gltBD gene to be modified to enhance its expression is not limited to the genes shown in SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:11, respectively, but can include genes homologous to SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:11, respectively.
  • the protein variant encoded by the ppc, pycA, gdhA ox gltBD gene can have a homology of not less than 80%, in another example not less than 90%, and in another example not less than 95 %, with respect to the entire amino acid sequence shown in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12, respectively, as long as the activity of the corresponding protein is maintained.
  • the phrase "protein variant” means proteins which have changes in the sequences, whether they are deletions, insertions, additions, or substitutions of amino acids. The number of changes in the variant proteins depends on the position in the three dimensional structure of the protein or the type of amino acid residue.
  • Homology between two amino acid sequences can be determined using the well-known methods, for example, the computer program BLAST 2.0, which calculates three parameters: score, identity and similarity.
  • substitution, deletion, insertion or addition of one or several amino acid residues can be conservative mutation(s) so that the activity is maintained.
  • the representative conservative mutation can be a conservative substitution.
  • conservative substitutions include substitution of Ser or Thr for Ala, substitution of GIn, His or Lys for Arg, substitution of GIu, GIn, Lys, His or Asp for Asn, substitution of Asn, GIu or GIn for Asp, substitution of Ser or Ala for Cys, substitution of Asn, GIu, Lys, His, Asp or Arg for GIn, substitution of Asn, GIn, Lys or Asp for GIu, substitution of Pro for GIy, substitution of Asn, Lys, GIn, Arg or Tyr for His, substitution of Leu, Met, VaI or Phe for He, substitution of He, Met, VaI or Phe for Leu, substitution of Asn, GIu, GIn, His or Arg for Lys, substitution of He, Leu, VaI or Phe for Met, substitution of Trp,
  • the ppc, pycA, gdhA or git BD gene can be a variant which hybridizes under stringent conditions with the nucleotide sequence complementary to the sequence shown in SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:11, respectively, or a probe which can be prepared from the nucleotide sequence, provided that it encodes a functional protein.
  • Stringent conditions include those under which a specific hybrid, for example, a hybrid having homology of not less than 60%, in another example not less than 70%, in another example not less than 80%, in another example not less than 90%, and and in another example not less than 95%, is formed and a non-specific hybrid, for example, a hybrid having homology lower than the above, is not formed.
  • stringent conditions are exemplified by washing one time or more, and in another example two or three times, at a salt concentration of 1 xSSC, 0.1% SDS, and in another example 0.1 x SSC, 0.1% SDS at 60 0 C. Duration of washing depends on the type of membrane used for blotting and, as a rule, can be what is recommended by the manufacturer.
  • the recommended duration of washing for the HybondTM N+ nylon membrane (Amersham) under stringent conditions is 15 minutes.
  • washing can be performed 2 to 3 times.
  • the length of the probe can be suitably selected depending on the hybridization conditions, and is usually 100 bp to 1 kbp.
  • Methods of gene expression enhancement include increasing the gene copy number. Introducing a gene into a vector that is able to function in a bacterium belonging to the genus Pantoea increases the copy number of the gene.
  • a plasmid which can be transformed include plasmids which are autonomously replicable in bacteria belonging to the genus Pantoea, for example, pUC19, pUC18, pBR322, RSFlOlO, pHSG299, pHSG298, pHSG399, pHSG398, pSTV28, pSTV29 (pHSG and pSTV can be obtained from Takara Bio), pMWl 19, pMWll[delta], pMW219, pMW218 (plasmids of pMW series can be obtained from Nippon Gene), and so forth.
  • Phage DNA can also be used as a vector, instead of a plasmid.
  • Gene expression can also be enhanced by introducing multiple copies of the gene into the bacterial chromosome by, for example, a method of homologous recombination, Mu integration, or the like.
  • Mu integration allows for the introduction of up to 3 copies of the gene into the bacterial chromosome.
  • Increasing the copy number of a gene can also be achieved by introducing multiple copies of the gene into the chromosomal DNA of the bacterium.
  • homologous recombination is carried out using a sequence having multiple copies of the gene, and these multiple copies function as targets in the chromosomal DNA.
  • Sequences having multiple copies in the chromosomal DNA include, but are not limited to repetitive DNA, or inverted repeats present at the end of a transposable element. Also it is possible to incorporate the gene into a transposon, and allow it to be transferred to introduce multiple copies of the gene into the chromosomal DNA.
  • Gene expression can also be enhanced by placing the DNA under the control of a potent promoter.
  • a potent promoter for example, the lac promoter, the trp promoter, the trc promoter, the P R , or the P L promoters of lambda phage are all known to be potent promoters.
  • the use of a potent promoter can be combined with multiplication of gene copies.
  • the effect of a promoter can be enhanced by, for example, introducing a mutation into the promoter to increase the transcription level of a gene located downstream of the promoter.
  • substitution of several nucleotides in the spacer between the ribosome binding site (RBS) and the start codon, especially the sequences immediately upstream of the start codon profoundly affect the translation of the mRNA. For example, a 20-fold range in the expression levels was found, depending on the nature of the three nucleotides preceding the start codon (Gold et al, Annu. Rev. Microbiol., 35, 365-403, 1981; Hui et al, EMBO J., 3, 623-629, 1984).
  • a nucleotide substitution into a promoter region of a gene on the bacterial chromosome, which results in a stronger promoter function.
  • the alteration of the expression control sequence can be performed, for example, in the same manner as the gene substitution using a temperature-sensitive plasmid, as disclosed in WO 00/18935 and JP 1-215280 A.
  • Bacteria producing L-aspartic acid or L-aspartic acid-derived metabolites include a bacterium which has been modified to have decreased activity of ⁇ -ketoglutarate dehydrogenase; decreased activity of citrate synthase; increased activity of phosphoenolpyruvate carboxylase or pyruvate carboxylase; and increased activity of glutamate dehydrogenase or glutamate synthase.
  • Bacteria can be further modified to have attenuated expression of the gene coding for aspartate ammonia-lyase (aspartase).
  • parent strains which can be used to derive L-threonine-producing bacteria include strains in which expression of one or more genes encoding an L- threonine biosynthetic enzyme are enhanced.
  • the bacterium is modified to enhance expression of one or more of the following genes:
  • mutant thrA gene which codes for aspartokinase homoserine dehydrogenase I resistant to feed back inhibition by threonine;
  • the thrA gene which encodes aspartokinase homoserine dehydrogenase I of Escherichia coli has been elucidated (nucleotide positions 337 to 2799, GenBank accession no.NC_000913.2, gi: 49175990).
  • the thrA gene is located between the thrL and thrB genes on the chromosome of E. coli K- 12.
  • the thrB gene which encodes homoserine kinase of Escherichia coli has been elucidated (nucleotide positions 2801 to 3733, GenBank accession no.NC_000913.2, gi: 49175990).
  • the thrB gene is located between the thrA and thrC genes on the chromosome of E. coli K- 12.
  • the thrC gene which encodes threonine synthase of Escherichia coli has been elucidated (nucleotide positions 3734 to 5020, GenBank accession no.NC_000913.2, gi: 49175990).
  • the thrC gene is located between the thrB gene and the yaaX open reading frame on the chromosome of E. coli K- 12. All three genes function as a single threonine operon.
  • the attenuator region which affects the transcription is desirably removed from the operon (WO2005/049808, WO2003/097839).
  • a mutant thrA gene which codes for aspartokinase homoserine dehydrogenase I and is resistant to feedback inhibition by threonine, as well as the thrB and thrC genes, can be obtained as one operon from the well-known plasmid pVIC40, which is present in the threonine producing E. coli strain VKPM B-3996. Plasmid pVIC40 is described in detail in U.S. Patent No. 5,705,371.
  • the rhtA gene is present at 18 min on the E. coli chromosome close to the glnHPQ operon, which encodes components of the glutamine transport system.
  • the rhtA gene is identical to ORPl (ybiF gene, nucleotide positions 764 to 1651, GenBank accession number AAA218541, gi:440181) and is located between the pexB and ompX genes.
  • the unit expressing a protein encoded by the ORFl has been designated the rhtA gene (rht: resistance to homoserine and threonine).
  • the asd gene of E. coli has already been elucidated (nucleotide positions 3572511 to 3571408, GenBank accession no. NC 000913.1, gi:16131307), and can be obtained by PCR (polymerase chain reaction; refer to White, TJ. et al., Trends Genet., 5, 185 (1989)) utilizing primers prepared based on the nucleotide sequence of the gene.
  • the asd genes from other microorganisms can be obtained in a similar manner.
  • the aspC gene of E. coli has already been elucidated (nucleotide positions 983742 to 984932, GenBank accession no. NC 000913.1, gi:16128895), and can be obtained by PCR.
  • the aspC genes of other microorganisms can be obtained in a similar manner.
  • L-lysine-producine bacteria examples include strains in which expression of one or more genes encoding an L-lysine biosynthetic enzyme are enhanced. Examples of such genes include, but are not limited to, genes encoding dihydrodipicolinate synthase (dapA), aspartokinase (lysC), dihydrodipicolinate reductase (dapB), diaminopimelate decarboxylase (lysA), diaminopimelate dehydrogenase (ddh) (U.S. Patent No.
  • ppc phosphoenolpyrvate carboxylase
  • aspartate semialdehyde dehydrogenease aspartase
  • aspA aspartase
  • the parent strains can have increased expression of the gene involved in energy efficiency (cyo) (EP 1170376 A), the gene encoding nicotinamide nucleotide transhydrogenase (pntAB) (U.S. Patent No. 5,830,716), the ybjE gene (WO2005/073390), or combinations thereof.
  • parent strains which can be used to derive L-lysine-producing bacteria also include strains having decreased or eliminated activity of an enzyme that catalyzes a reaction for generating a compound other than L-lysine by branching off from the biosynthetic pathway of L-lysine.
  • the enzymes that catalyze a reaction for generating a compound other than L-lysine by branching off from the biosynthetic pathway of L-lysine include homoserine dehydrogenase, lysine decarboxylase (U.S. Patent No. 5,827,698), and the malic enzyme (WO2005010175).
  • Methods are described for producing L-aspartic acid or L-aspartic acid-derived metabolites which include cultivating the bacterium as described herein in a culture medium to produce and excrete the L-aspartic acid or L-aspartic acid-derived metabolite into the medium, and collecting the produced L-aspartic acid or L-aspartic acid-derived metabolite from the medium.
  • the cultivation, collection, and purification of L-aspartic acid or L-aspartic acid-derived metabolites from the medium and the like can be performed in a manner similar to conventional fermentation methods wherein an amino acid is produced using a bacterium.
  • the medium used for culture can be either a synthetic or natural medium, so long as the medium includes a carbon source, a nitrogen source, minerals, and, if necessary, appropriate amounts of nutrients which the bacterium requires for growth.
  • the carbon source can include various carbohydrates such as glucose and sucrose, and various organic acids. Depending on the assimilation mode of the chosen microorganism, alcohol including ethanol and glycerol can be used.
  • As the nitrogen source various ammonium salts such as ammonia and ammonium sulfate, other nitrogen compounds such as amines, a natural nitrogen source such as peptone, soybean-hydrolysate, and digested fermentative microorganism can be used.
  • potassium monophosphate magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, calcium chloride, and the like can be used.
  • vitamins thiamine, yeast extract, and the like, can be used.
  • the cultivation can be performed under aerobic conditions, such as by shaking and/or stirring with aeration, at a temperature of 30 to 36°C, and in another example 32 to 34°C.
  • the pH of the culture is usually between 5.0 and 7.0, and in another example between 6.0 and 6.5.
  • the pH of the culture can be adjusted with ammonia, calcium carbonate, various acids, various bases, and buffers. Usually, a 1 to 5 -day cultivation leads to accumulation of the target L-amino acid in the liquid medium.
  • solids such as cells can be removed from the liquid medium by centrifugation or membrane filtration, and then the L-amino acid can be collected and purified by ion-exchange, concentration, and/or crystallization methods.
  • the DNA fragment containing a kanamycin resistance gene flanked with attL and attR sites of phage ⁇ with primers presented in Table 1 was amplified with PCR. Primers used in the reaction were homologous with at least 40bp of the target sites of P. ananatis genome on their 5'- ends.
  • pMWl ⁇ 8-( ⁇ attL-Km ⁇ - ⁇ attR) plasmid (RU application 2006134574, WO2008/075483) was used as a template in all the reactions.
  • the obtained DNA fragments were treated for 2 or 3 hours with Dpnl restrictase which recognizes the methylated GATC site to eliminate pMWl 18-( ⁇ Z-Km r - ⁇ //i?).
  • pMW- IntXis-cat plasmid was electroporated to the selected plasmid-less integrant by the same procedure as for the electroporation of the PCR- generated fragments. After electroporation the cells were plated on LB-agar containing 0.5% glucose, 0.5x M9 salt solution and chloramphenicol (50mg/L) and incubated at 37°C overnight to induce synthesis of the Int/Xis proteins. The grown clones were replica-plated on LB-plates with and without kanamycin to select Km s variants. The selected Km s clones were re-checked by PCR with corresponding test primers.
  • Cm R the pMW-IntXis helper plasmid (WO2005010175) was used. Selection of Cm s clones was performed as above. But in this case, cells after electroporation were plated on a medium containing 800 mg/L ampicillin.
  • the desirable plasmids were electroporated to the corresponding strains by the method described above for electroporation of DNA fragments.
  • the 3 ⁇ ::pycA strain was constructed via integration of the mini-Mu cassette carrying the pycA gene from Sinorhizobium meliloti under control of the P, flC promoter and canonical SD sequence AGGAGG.
  • the integrative plasmid pMIV-P toc - pycA was constructed (see Example 2).
  • the pMIV-P tac -#yc ⁇ plasmid was electroporated to 3 ⁇ -S strain (marker- less) (see Table 7) harboring phMIV-1 helper plasmid (see Reference Example 3) providing expression of the Mu integrase according to the procedure described above.
  • the 3 ⁇ -S strain is a marker-less strain of the 3 ⁇ strain (SCIl(O)AaSpAAsUcAAgItA). After electroporation, cells were incubated at 37°C for induction of the integrase synthesis. Cells were plated on L-agar containing 25mg/L chloramphenicol. pMIV -P, ac -pycA carried two antibiotic resistance markers: cat inside the integrative cassette and bla on the vector part of the plasmid. The grown clones were replica-plated and Ap clones were selected. The selected clones did not contain the integrative plasmid. PCR analysis proved the presence of the pycA gene in the genome of the selected clones.
  • the obtained integrants were cured from the helper plasmid. To that, cells were seeded in LB medium and incubated without agitation at 37°C in 3 days. After that, cells were plated on L-agar with addition of chloramphenicol (25mg/L) and incubated at 34°C overnight. The grown clones were replica plated and Tc s Cm R variants were selected and designated 3 ⁇ ::pycA.
  • 5 ⁇ P2-36S strain is a marker-less derivative of the 5 ⁇ -S strain carrying Appc mutation and the E. colippc K620S gene integrated to the genome by the same Mu- dependent procedure as was used for the 3 ⁇ ::pycA strain construction.
  • the k ⁇ n gene flanked by ⁇ ttR/L was amplified by PCR, using primers Dppc-3' (SEQ ID NO: 73) and attR3-XbaI-HindIII (SEQ ID NO: 76).
  • Genomic DNA isolated from P. ⁇ n ⁇ n ⁇ tis SC 17(0) strain Ptac-lacZ (RU application 2006134574, WO2008090770) was used as a template for PCR.
  • the fragment containing the terminator of the leader peptide of the E. coli threonine operon (Tthr) was constructed by PCR.
  • mashl SEQ ID NO: 74
  • mash2 SEQ ID NO: 75
  • Dppc-5' SEQ ID NO: 72
  • Tthr5'-Xbal SEQ ID NO: 77
  • the resulting DNA fragment was used as a template for PCR with Dppc-5'(SEQ ID NO: 72) and Tthr5'-Xbal (SEQ ID NO: 77) primers to create the fragment with a Xb ⁇ l recognition site on its 5 '-end, which is necessary to join the integrative cassette and homologous arm for integration on the 3 '-end.
  • the fragments including Tthr and the removable Km R marker were digested by Xb ⁇ l restrictase and then ligated.
  • the ligated mixture was electroporated to the SC17(0)/RSF-Red-TER (RU application 2006134574) strain for integration according to the procedure for ⁇ Red-dependent integration described above.
  • Integrants were selected on LB-agar plates with kanamycin (40mg/l). The chromosome structure of the integrants was confirmed by PCR using ppc-tl (SEQ ID NO: 78) and ppc-t2 (SEQ ID NO: 79) oligonucleotides as primers. The resulting strain was named SC17(0) ⁇ ppc.
  • the constructed deletion was transferred to 5 ⁇ -S by the chromosome electroporation procedure.
  • 200 ng of genomic DNA isolated from SC17(0) ⁇ ppc using the Genomic DNA Purification Kit provided by "Fermentas” was electro-transformed to 5 ⁇ -S.
  • the cultivation conditions were the same as for the Red- dependent integration procedure except for the addition of IPTG.
  • Preparation of the electrocompetent cells was the same as for Red-dependent integration.
  • the obtained integrants were verified by PCR using ppc-tl (SEQ ID NO: 78) and ppc-t2 (SEQ ID NO: 79) oligonucleotides as primers.
  • the resulting strain was named 5 ⁇ P.
  • the high L-GIu concentration was used to simulate the presence of the glutamate dehydrogenase.
  • the selected strain was cured from the chloramphenicol resistance marker using the ⁇ lnt/Xis-dependent procedure (see above).
  • the resultant strain was named 5 ⁇ P2-36S.
  • 5 ⁇ P2R strain was obtained from 5 ⁇ P2-36S as a spontaneous Asp R mutant selected on the M9 plates containing 10 g/L glucose and 30 g/L L- Asp (L-aspartic acid), pH5.5 having the same producing ability as the parental strain.
  • Section B was adjusted by NaOH to have pH 6.5. Sections B and C were sterilized separately.
  • Seed Plates containing LB-M91/2 medium (LB medium enriched with 0.5x M9 salt solution and 0.5% glucose) with addition of the appropriate antibiotic seeded and incubated at 34°C overnight.
  • the DNA fragment which includes a coding part of the E. coli aspC gene linked with canonical SD-sequence AGGAGG was generated in PCR with the primers E-aspC5'KI (SEQ ID NO: 92) and E-aspC3'BI (SEQ ID NO: 93).
  • Chromosomal DNA isolated from the E. coli strain MGl 655 was used as template in the reaction.
  • the strain MGl 655 can be obtained from American Type Culture Collection. (P.O. Box 1549 Manassas, VA 20108, United States of America).
  • the obtained fragment was digested with Kpnl and BamRl restrictases and ligated with pMWl 18-PlacUV5-lacI vector (Skorokhodova, A. Yu et al, Biotekhnologiya (Rus), 5, 3-21 (2004)) which had been digested with the same endonucleases.
  • the ligated mixture was transformed to E. coli strain TGl (J. Sambrook et al., Molecular Cloning, 1989) and plasmid DNA was isolated from the clones grown on LB plates with ampicillin (100mg/L).
  • the plasmids carrying the desirable insertion were electroporated to the SC17(0) ⁇ aspC ⁇ tyrB strain and several plasmids which resulted in auxotrophy of the strain to L-aspartic acid were selected.
  • One of these plasmids was electro-transformed to 3 ⁇ -S/RSFGP strain (see below) and specific aspartate aminotransferase activity was assayed in crude extracts of the 3 ⁇ - S/RSFGP harboring pMW-EaspC.
  • the plasmid-less strain was used as a control.
  • Table 4 indicate that the pMW-EaspC plasmid provides an increase of aspartate aminotransferase activity in 3 ⁇ -S/RSFGP strain by 1.5 times.
  • the E. colippc ⁇ 2 gene coding for PEP-carboxylase resistant against inhibition by aspartic acid was sub-cloned from the pTK620S plasmid (Masato Yano and Katsura Izui, Eur. J. Biochem. FEBS, 247, 74-81, 1997) to the pMIV-5JS plasmid (RU patent application 2006132818, EP 1942183) in two steps. At first, the Sall-Sphl fragment of pTK620S was sub-cloned into Sall-Sphl recognition sites of pMIV5-JS.
  • the obtained pMIV-ppc-5'plasmid carries a large 5'-terminal portion of the p/7c K620S gene.
  • the 3'-proximal portion of the ppc gene was amplified in PCR with primers ppc-Sphl (SEQ ID NO: 94) and ppc-Hindlll (SEQ ID NO: 95) and the pTK620S plasmid as template.
  • This fragment and pMIV-ppc-5' were digested with Sphl and Hindlll restrictases and ligated.
  • the ligated mixture was electroporated to E.coli strain MG1655 ⁇ ppc (see Reference Example 4).
  • telomere sequence a DNA fragment containing the coding part of the pycA gene from Sinorhizobium meliloti was generated in PCR with primers PycSm5-LNX (SEQ ID NO: 96) and pycSm3-Sal (SEQ ID NO: 97). Chromosomal DNA isolated from the S".
  • meliloti type strain DSM 30135, ATCC 9930, VKPM B- 9293
  • VKPM All-Russian Collection of Industrial Microorganisms (VKPM) (Russia, 117545 Moscow, 1 Dorozhny proezd, 1) was used as a template in this reaction. This strain can also be obtained from ATCC.
  • the obtained DNA fragment was digested with Sail and Xbal restrictases and ligated with the pMIV5-JS integrative plasmid which had been treated with the same enzymes.
  • the ligated mixture was transformed to E. coli strain TGl and plasmid DNA was isolated from the clones which grew on LB plates with ampicillin (100mg/L) and chloramphenicol (50mg/L).
  • Three plasmids carrying the desirable insertion were selected. These plasmids carrying the promoter-less gene pycA were designated pMIV- pycA (Fig. 2). All three obtained plasmid probes were used for the cloning of P toc promoter in front of the pycA gene.
  • the DNA fragment containing P toc was generated by PCR with primers J56 (SEQ ID NO: 108) and J57(KpnBgl) (SEQ ID NO: 109).
  • the pDR540 plasmid (GenBank accession number U13847, "Pharmacia") was used as a template in this reaction.
  • Primer J56 contains the site for Xbal restrictase at the 5 '-end thereof.
  • Primer J57(KpnBgl) contains sites for Kpnl amd BgHl restrictase at the 5 '-end thereof.
  • the resulting DNA fragment was digested with Kpnl and Klenow fragment of DNA polymerase I to obtain the blunt ends.
  • the fragment was digested with Xbal and ligated with pMIV-pycA plasmid digested with Xbal and Ec/136II (the last enzyme produces the blunt ends).
  • the resulting ligated mixture was transformed to the E. coli strain MG1655 ⁇ ppc. After transformation, cells were plated on M9 glucose minimal medium to select the clones prototrophic to L- glutamic acid. Plasmid DNA from the selected clones was isolated and the structure of the resulting pMIV-Ptac-pycA plasmid was proven by restriction analysis.
  • RSFGP plasmid carrying ppc and gdhA genes from E. coli was constructed on the basis of the RSFCPG plasmid containing the git A, ppc and gdhA genes (US patent application 20070134773).
  • 5'- end phosporylated primers S ⁇ Q ID NO: 118 and 119 were used for PCR to obtain a big part of the RSFCPG plasmid without the git A gene using TaKaRa La TaqTM DNA polymerase (TaKaRa Bio Inc., Japan). The resulting 14 kb PCR fragment was purified and ligated. Thus, the RSFGP plasmid was obtained.
  • pMWgdhA plasmid carrying the gdhA gene from E. coli was obtained by ligation of the DNA fragment carrying the gdhA gene from E. coli into pMWl 19 vector.
  • the DNA fragment carrying the gdhA gene from E. coli was obtained by PCR using primers S ⁇ Q ID NO: 120 and 121.
  • Primer S ⁇ Q ID NO: 120 contains a Sail restriction site at the 5 '-end thereof
  • primer S ⁇ Q ID NO: 121 contains Hindlll restriction site at the 5 '-end thereof.
  • the resulting DNA fragment was treated with Sail and Hindlll restrictases and ligated into a pMWl 19 vector previously treated with the same restrictases.
  • Example 3 Function of the genes involved in L-aspartatic acid/L- glutamic acid metabolism in P. ananatis.
  • E. coli two enzymes possess aspartate aminotransferase activity. They are aspartate aminotransferase encoded by the aspC gene and aromatic amino acids aminotrasferase, the product of the tyrB gene. Only simultaneous inactivation of the aspC and tyrB genes leads to Asp auxotrophy in E. coli (Reitzer, L. J., Ammonia assimilation and the biosynthesis of glutamine, glutamic acid, aspartic acid, asparagine, L-alanine, and D-alanine. In Neidhardt, F. C. (Ed. in Chief), R. Curtiss III, J.L. Ingraham, E.C.C.
  • P. ananatis is a member of Enterobacteriaceae family, and is closely related to E. coli.
  • the putative aspC and tyrB genes were found in the P. ananatis genome using the "Genome” program. These genes were inactivated in P. ananatis SC 17(0) strain using the procedure of ⁇ Red-dependent integration of PCR generated DNA fragments (see Reference Example 1), which were previously adopted for use in this organism (RU application 2006134574).
  • oxaloacetate is a precursor for aspartic acid synthesis and L-glutamic acid is a donor of amides.
  • L-glutamic acid is a donor of amides.
  • an increase of the oxaloacetate intracellular level is necessary.
  • PEP carboxylases and pyruvate carboxylases are inhibited by L-aspartic acid.
  • PEP carboxylase from E. coli is sensitive to this inhibitor (Wohl, R.C. & Markus, G., J. Biol. Chem., Vol. 247(18), pp.
  • the constructed strain could not use aspartic acid as a sole carbon source absolutely (Table 5) and did not display aspartase activity. Therefore, the aspA gene coding for aspartase was identified. It has been shown that, as in E. coli, the aspartase reaction is the major way for aspartic acid utilization in P. ananatis. The aspA gene must be inactivated in an aspartic acid-producing strain to avoid product utilization by the cells.
  • the fumarate which is formed in the aspartase reaction is converted to malate and, after that, to oxaloacetate in TCA.
  • oxaloacetate can be converted to citrate in citrate synthase reaction or decarboxylated to PEP in PEP carboxykinase reaction or to Pyr by oxaloacetate decarboxylase.
  • malic enzyme catalyzes decarboxylation of malate to pyruvate. It was published elsewhere (H Ozaki, J Shiio. Production of lysine by pyruvate kinase mutants of Brevibacterium flavum, Agr. Biol.
  • citrate synthase reaction is the major way of unproductive waste of oxaloacetate.
  • ⁇ -ketoglutarate utilization (due to AsucA mutation) must be blocked, and re-amination of ⁇ -ketoglutarate at a high rate is necessary.
  • Animation of ⁇ -ketoglutarate to L-glutamic acid can be carried out in glutamate dehydrogenase or glutamate synthase reactions. It is well known in Enterobacteriaceae that glutamate dehydrogenase and glutamate synthase/glutamine synthetase form two alternative pathways for L-glutamic acid synthesis. Bacteria use only one of these pathways depending on the availability of energy and nitrogen. In E.
  • the P. ananatis genome does not contain ORFs coding for close homologues of E. coli glutamate dehydrogenase or glutamate synthase. Instead, it contains the gltB gene coding for a close homologue of a large subunit of glutamate synthase from Agrobacterium tumefaciens, and the gdhA gene coding for close homologue of glutamate dehydrogenase from Salmonella typhimurium.
  • We have deleted the gltB gene in P. ananatis see Reference Example 1). The resulting strain has proven to be a strong auxotroph to L-GIu (L-GIu requirement 0.5 g/L).
  • glutamate synthase/glutamine synthetase reactions are the only pathways for the synthesis of L- glutamic acid in P. ananatis.
  • deletion of the putative gdhA gene as well as replacing its regulatory region with a strong V tac promoter linked to a consensus SD sequence did not significantly change the growth of P. ananatis with glucose and L-glutamic acid as the sole carbon sources.
  • glutamate dehydrogenase activity was not detected in P. ananatis crude extracts.
  • the gdhA gene found by computer analysis in this organism is inactive, at least under the chosen cultivation conditions. Therefore, the introduction of a foreign glutamate dehydrogenase or increase of glutamate synthase activity could be necessary for high-performance L- aspartic acid production.
  • enzymes including aspartate ammonia-lyase (aspartase), glucose dehydrogenase and malate dehydrogenase. It is also desirable to increase activity of aspartate aminotransferase.
  • Table 7 Test tube fermentation of the 3 ⁇ -S/RSFGP strain and the strains lacking one of the genetic factors necessary for L- Asp production. 48-hour cultivation; initial glucose concentration 40g/L, initial L-GIu concentration 3g/L. ImM IPTG was added for the strains harboring pMWaspC. Average data for 3 independent cultures are represented.
  • Example 5 Decrease of the unproductive conversion of PEP to Pyr due to inactivation of the pykA and pykF genes.
  • the 3 ⁇ -S (marker-less SC ⁇ 7(0) ⁇ aspA ⁇ sucAAgltA) strain transformed with the RSFGP plasmid carrying the ppc and gdhA genes from E. coli resulted in accumulation of L- Asp up to 0.7g/L in test-tube cultivation. At the same time, accumulation of VaI, Leu and Ala up to 2-3g/L was observed.
  • ⁇ #y£A:: ⁇ attL-Tc R - ⁇ attR and Apyk ⁇ :. ⁇ a.UL- Km R - ⁇ attR deletions were introduced step by step to 3 ⁇ -S, which is the marker-less derivative of 3 ⁇ . The resulting strains were named 4 ⁇ and 5 ⁇ , respectively.
  • the 5 ⁇ strain was cured from the selective markers according to the above- described procedure.
  • the resulting strain 5 ⁇ -S was electro transformed with RSFGP plasmid to increase the PEP-carboxylase and glutamate dehydrogenase activities.
  • 5 ⁇ -S/RSFGP strain showed higher accumulation of aspartic acid than the control strain 3 ⁇ /RSFGP (Table 7).
  • the SC 17(0) ⁇ zwf ⁇ pzwf strain was constructed and the activities of glucose-6P dehydrogenase were determined in this strain, SC 17(0), and in SC17(0) ⁇ zwf. NAD-dependent activity was absent in all strains. NADP-dependent glucose-6P dehydrogenase activity was decreased at least 50 times in the strains carrying deletion of the chromosome zwf gene. Cells for this experiment were grown on glucose- containing medium. We have concluded that the chromosome zwf gene encodes NADP-dependent glucose-6P dehydrogenase whereas the pzwf gene is not expressed under these conditions.
  • the coding part of the /?zw/ ⁇ gene was amplified by PCR using primers pzwf-5 (SEQ ID NO: 98) and pzwf-3 (SEQ ID NO: 99), and genomic DNA isolated from P. ananatis SC 17 strain (US patent 6,596,517) as a template.
  • Primer pzwf-5 (SEQ ID NO: 98) contains the site formal restrictase at the 5 '-end thereof.
  • Primer pzwf-3 (SEQ ID NO: 99) contains the site for BamHl restrictase at the5'-end thereof.
  • the resulting DNA fragment was treated with Xbal and BamRl restrictases and was cloned into the Xbal-BamHl sites of the RSF-based vector RSFPlaclacI (see Reference Example 1) under control of the P/ ⁇ c uvs promoter.
  • the resulting plasmid RSFP /ac -pzwf (Fig 5) was isolated from 4 independent plasmid clones and electro-transformed to the SC17(0) ⁇ zwf ⁇ pgi ⁇ gcd strain, and then plated on glucose minimal medium.
  • the SC17(0) ⁇ zwf ⁇ pgi ⁇ gcd and SC17(0) ⁇ pgi ⁇ gcd strains were used as controls.
  • Glucose-6P dehydrogenase activities were determined in crude extracts of all 4 transformants (assay is described in the Example section below). As it is shown in Table 8, the plasmid isolated from clone 1 resulted in undetectable levels of Zwf (glucose-6P dehydrogenase) activity, while the plasmid isolated from clones 4, 5 and 7 carried a copy of the plasmid zwf gene encoding glucose-6P dehydrogenase with double NAD/NADP co factor specificity. Moreover, the level of NAD-dependent activity was significantly higher than that of NADP-dependent activity in these clones.
  • the pgnd gene was cloned into the RSFPlaclacI plasmid under the control of the P /flC uvs promoter using the primers pgnd-5 (SEQ ID NO: 100) and pgnd-3 (SEQ ID NO: 101) for PCR-amplification of its coding part.
  • Primer pgnd-5 (SEQ ID NO: 100) contains the site formal restrictase at the5'-end thereof.
  • Primer pgnd-3 (SEQ ID NO: 101) contains the site for BamHl restrictase at the5'-end thereof.
  • the DNA fragment obtained by PCR was treated with Xbal and BamHl restrictases and cloned into Xbal-BamHl sites of the RSF-based vector RSFPlaclacI.
  • the resulting plasmid RSFPlac-pgnd is depictured in Fig. 5.
  • Example 7 Gluconic acid accumulation in aspartic acid fermentation process. Further improvement of aspartic acid production due to inactivation of glucose dehydrogenase.
  • gluconic acid is formed from glucose via a glucose dehydrogenase reaction.
  • the gcd gene coding for glucose dehydrogenase was deleted in the 5 ⁇ P2R strain according to the above-described ⁇ Red-dependent procedure using oligonucleotides gcd-attR (SEQ ID NO: 49) and gcd-attL (SEQ ID NO: 50) as primers for generation of the integrative DNA fragment; oligonucleotides gcd-testl (SEQ ID NO: 51) and gcd-test2 (SEQ ID NO: 52) were used for PCR verification of the obtained integrants.
  • the resulting strain 5 ⁇ P2RG was electroporated with pMWgdhA and checked in test tube cultivation. Inactivation of glucose dehydrogenase led to an increase of aspartic acid accumulation by 3.3 times for the plasmid-less strains and by 1.4 times for the plasmid strains (Table 10). Table 10. Effects of the ⁇ gcd mutation on aspartic acid production by P. ananatis. 72- hour cultivation; initial glucose concentration 40g/L, initial L-GIu concentration 3g/L. Average data for 3 independent cultures are represented.
  • Example 8 Further improvement by amplification of the pzwfor psnd gene.
  • the RSFP lac-pzwf and RSFPlac-pgnd plasmids were introduced into the 5 ⁇ P2- 36S strain by the electroporation procedure (see above).
  • the resulting plasmid strains gave significantly increased aspartic acid accumulation in comparison with the plasmid-less parental strain.
  • Amplification of the/?zw/gene led to a 2.6-fold increase of the product accumulation, amplification of the pgm/ gene gave a 1.4-fold increase of aspartic acid accumulation in test tube cultivation (Table 11).
  • Example 9 Further improvement of aspartic acid production by inactivation of malate dehydrogenase.
  • the mdhA gene coding for malate dehydrogenase was deleted in the 5 ⁇ P2R strain according to the above-described ⁇ Red-dependent procedure using oligonucleotides mdhA-attR (SEQ ID NO: 88) and mdhA-attL (SEQ ID NO: 89) as primers for generation of the integrative DNA fragment; oligonucleotides mdhA-testl (SEQ ID NO: 90) and mdhA-test2 (SEQ ID NO: 91) were used for PCR verification of the obtained integrants.
  • the resulting strain 5 ⁇ P2RM was cured from the kanamycin resistance marker using the above-described ⁇ lnt/Xis-dependent procedure.
  • the pMWgdhA plasmid was introduced into the marker-less derivative of 5 ⁇ P2RM and to 5 ⁇ P2R.
  • the results of the experiment on test tube cultivation of the obtained strains represented in Table 12 show a significant positive effect of the AmdhA mutation on aspartic acid accumulation and yield for the both plasmid and plasmid-less variants.
  • RSFPlaclacI (Fig. 6) is a derivative of the RSFPlaclacIsacBcat plasmid previously described in Russian patent application (RU 2006134574).
  • the RSFPlaclacIsacBcat plasmid which is also named pRSFsacB, has been disclosed by Katashkina, J.I. et al. (Use of the ⁇ Red-recombineering method for genetic engineering of Pantoea ananatis. BMC Molecular biology 2009, 10:34).
  • To construct this plasmid Red-dependent integration of the generated in vitro short DNA fragment, which includes a polylinker site into the RSFPlacIsacBcat plasmid, was performed.
  • the oligonucleotides DeI-F (SEQ ID NO: 102) and DeI-R (SEQ ID NO: 103) 200 ng of each were annealed and extended in the polymerase chain reaction mixture prepared from the reagents provided by "Fermentas" accordingly to the manufacturer's instructions (temperature profile was 95°C for 2min, 50°C for 1 min, 72°C for 2 min).
  • the probe was precipitated with ethanol, washed with 70% ethanol twice and dissolved in 10 ⁇ l of fresh de-ionized water.
  • the MG1655/pKD46 strain was used as a recipient strain for Red-dependent integration.
  • Preparation of the electrocompetent cells was as described by Datsenko, K. A. and Wanner, B.L. (Proc. Natl. Acad. Sci. USA, 97, 12, p 6640-6645 (2000)).
  • 200 ng of the prepared DNA fragment and 100 ng of the RSFPlaclacIsacBcat plasmid were used for electroporation.
  • Electroporation was performed using a Gene Pulser apparatus (BioRad, USA, version 2-89). Pulse time was 5 msec, and electric field strength was 12.5 kV/cm. 1 ml of SOC medium was added to the cell suspension immediately after electroporation.
  • the cells were cultivated at 37°C for 2 hours, spread on LB agar containing 50 ⁇ g/ml of chloramphenicol, 5% sucrose, and 1 mM IPTG and cultivated at 37°C overnight.
  • the integrative DNA fragment contained flanks homologous to the upstream and downstream regions of the sacB gene coding for levansucrase. Expression of this gene is highly toxic for many bacterial species and is routinely used as a contra-selective marker (Gay, P. et al., J. Bacterid., 164, 918-921 (1985)).
  • Cm R Suc R clones Fifteen Cm R Suc R clones were selected in this experiment. Plasmid DNA was isolated from these clones, transformed to the E. coli TGl strain and re-isolated from it for the restriction analysis. After digestion of the isolated DNA probes with the Hindlll, Sphl, Pstl, Sail, BamHI, BgIII, Pvul, and Xbal restriction endonucleases, the clone containing the polylinker site of the expected structure was selected.
  • a strain in which the ppc gene is deleted was constructed by the method initially developed by Datsenko, K.A. and Wanner, BX. (Proc. Natl. Acad. Sci. USA, 2000, 97(12), 6640-6645) called "Red-driven integration".
  • the DNA fragment containing the Cm R marker encoded by the cat gene was obtained by PCR, using primers pps-attR (SEQ ID NO: 111) and ppc-attL (SEQ ID NO: 112), and plasmid pMWl 18-attL-Cm-attR as a template (WO2005010175).
  • Primer pps-attR contains both a region complementary to the region located at the 5' end of the ppc gene and a region complementary to the attR region. Primer pps-attR contains both a region complementary to the region located at the 3' end of the ppc gene and a region complementary to the attL region.
  • a 1,7 kbp PCR product was obtained and purified in agarose gel, and was used for electroporation of the E. coli strain MG 1655 (ATCC 700926), which contains the plasmid pKD46 having a temperature-sensitive replication.
  • the plasmid pKD46 (Datsenko, K.A. and Wanner, B.L., Proc. Natl. Acad. Sci. USA, 2000, 97:12:6640-45) includes a 2,154 nucleotide DNA fragment of phage ⁇ (nucleotide positions 31088 to 33241, GenBank accession no.
  • J02459 contains genes of the ⁇ Red homologous recombination system ( ⁇ , ⁇ , exo genes) under the control of the arabinose-inducible P araB promoter.
  • the plasmid pKD46 is necessary for integration of the PCR product into the chromosome of strain MG 1655.
  • Electrocompetent cells were prepared as follows: E. coli MG1655/pKD46 was grown overnight at 30 °C in LB medium containing ampicillin (100 mg/1), and the culture was diluted 100 times with 5 ml of SOB medium (Sambrook et al, "Molecular Cloning: A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press, 1989) containing ampicillin and L-arabinose (1 mM). The cells were grown with aeration at 30°C to an OD OOO of «0.6, and then were made electrocompetent by concentrating 100-fold and washing three times with ice-cold deionized H 2 O. Electroporation was performed using 70 ⁇ l of cells and «100 ng of the PCR product.
  • the mutants having the ppc gene deleted and marked with the Cm resistance gene were verified by PCR.
  • Locus-specific checking primers ppc-testl (SEQ ID NO: 112) and ppc-test2 (SEQ ID NO: 113) were used in PCR for the verification.
  • the PCR product obtained in the reaction with the cells of parental ppc + strain MG1655 as a template was 2,8 kbp in length.
  • the PCR product obtained in the reaction with the cells of mutant strain as the template was 1.7 kbp in length.
  • the mutant strain was named MG1655 ⁇ ppc::cat.
  • Cm marker was excised from the chromosome using standard techniques (int-xis system) described in WO2005010175. Length of the DNA obtained in the PCR using primers ppc-testl and ppc-test2 in the case when the Cm marker is excised was 280 bp.
  • the reaction mixture contained 10OmM TRIS HCl (pH7.5), 1OmM L- Asp (pH7.0), 5mM ⁇ -ketoglutarate (pH7.0), 0,ImM pyridoxal phosphate. Oxaloacetate formation was detected by measuring the absorption at 265 nm.
  • Cells were collected by centrifugation, washed by 5OmM potassium phosphate buffer pH7.5, and disrupted by sonication. The activity determination was conducted in the coupled reaction with malate dehydrogenase.
  • the reaction mixture included: 10OmM TRIS HCl (pH7.5), 5mM PEP, 4mM DTTE, 5mM MnSO 4 , 0.15mM NADH, 10OmM NaHCO 3 , O.lmM Acetyl-CoA, 2u/ml malate dehydrogenase. The change in NADH extinction at 340 nm was measured. The reactions without PEP or Acetyl-CoA were used as controls.
  • the reaction mixture contained 5OmM TRIS-HCl (pH 8.0), 4mM NAD + /NADP + , 2mM MgCl 2 and 4mM 6P-gluconate. The change in NADH extinction at 340 nm was measured. The average data for two independent cultures are shown in each case.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une bactérie appartenant au genre Pantoea qui a été modifiée pour obtenir une activité réduite de α-cétoglutarate déshydrogénase ; une activité réduite de citrate synthase ; une activité accrue de phosphoénolpyruvate carboxylase ou de pyruvate carboxylase ; et une activité accrue de glutamate déshydrogénase ou de glutamate synthase. Cette bactérie possède la capacité de produire de l'acide L-aspartique ou des métabolites dérivés de l'acide L-aspartique, tels que L-thréonine, L-lysine, L-méthionine et L-homosérine. L'invention concerne également un procédé de production d'acide L-aspartique ou de métabolites dérivés de l'acide L-aspartique utilisant la bactérie.
PCT/JP2009/067449 2008-09-30 2009-09-30 Bactérie appartenant au genre pantoea produisant un acide l-aspartique ou des métabolites dérivés de l'acide l-aspartique et procédé de production d'acide l-aspartique ou de métabolites dérivés de l'acide l-aspartique WO2010038905A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2008138615/10A RU2411289C2 (ru) 2008-09-30 2008-09-30 Бактерия, принадлежащая к роду pantoea, - продуцент l-аспартата или метаболита, являющегося производным l-аспартата, и способ получения l-аспартата или метаболита, являющегося производным l-аспартата
RU2008138615 2008-09-30

Publications (1)

Publication Number Publication Date
WO2010038905A1 true WO2010038905A1 (fr) 2010-04-08

Family

ID=41349266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/067449 WO2010038905A1 (fr) 2008-09-30 2009-09-30 Bactérie appartenant au genre pantoea produisant un acide l-aspartique ou des métabolites dérivés de l'acide l-aspartique et procédé de production d'acide l-aspartique ou de métabolites dérivés de l'acide l-aspartique

Country Status (2)

Country Link
RU (1) RU2411289C2 (fr)
WO (1) WO2010038905A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087139A2 (fr) 2010-01-15 2011-07-21 Ajinomoto Co.,Inc. Bactérie de la famille enterobacteriaceae produisant de l'acide l-aspartique ou des métabolites dérivés de l'acide l-aspartique et procédé de fabrication d'acide l-aspartique ou de métabolites dérivés de l'acide l-aspartique
WO2015199396A1 (fr) * 2014-06-23 2015-12-30 씨제이제일제당 주식회사 Microorganisme produisant de l'o-acétyl homosérine et procédé de production d'o-acétyl homosérine à l'aide dudit microorganisme
CN108866028A (zh) * 2017-05-09 2018-11-23 中国科学院微生物研究所 一种氨基裂解酶突变体蛋白及其编码基因与应用
WO2021060438A1 (fr) 2019-09-25 2021-04-01 Ajinomoto Co., Inc. Procédé de production d'acides l-aminés par fermentation bactérienne
JP2023506053A (ja) * 2020-01-30 2023-02-14 シージェイ チェイルジェダング コーポレイション クエン酸シンターゼの活性が弱化した新規な変異型ポリペプチド及びそれを用いたｌ－アミノ酸生産方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0955368A2 (fr) * 1998-03-18 1999-11-10 Ajinomoto Co., Ltd. Bactérie produisant de l'acide glutamique et procédé de préparation de l'acide glutamique
EP1462523A2 (fr) * 1998-03-18 2004-09-29 Ajinomoto Co., Inc. Bactérie produisant de l'acide glutamique et procédé de préparation de l'acide glutamique
WO2005085419A1 (fr) * 2004-03-04 2005-09-15 Ajinomoto Co., Inc. Micro-organisme producteur d'acide l-glutamique et procede de production d'acide l-glutamique
WO2007017710A1 (fr) * 2005-08-11 2007-02-15 Metabolic Explorer Procede de preparation d'aspartate et d'acides amines derives tels que la lysine, la threonine, l'isoleucine, la methionine, l'homoserine, ou la valine a l'aide d'un micro-organisme a expression d'isocitrate lyase et/ou de malate synthase amelioree

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0955368A2 (fr) * 1998-03-18 1999-11-10 Ajinomoto Co., Ltd. Bactérie produisant de l'acide glutamique et procédé de préparation de l'acide glutamique
EP1462523A2 (fr) * 1998-03-18 2004-09-29 Ajinomoto Co., Inc. Bactérie produisant de l'acide glutamique et procédé de préparation de l'acide glutamique
WO2005085419A1 (fr) * 2004-03-04 2005-09-15 Ajinomoto Co., Inc. Micro-organisme producteur d'acide l-glutamique et procede de production d'acide l-glutamique
WO2007017710A1 (fr) * 2005-08-11 2007-02-15 Metabolic Explorer Procede de preparation d'aspartate et d'acides amines derives tels que la lysine, la threonine, l'isoleucine, la methionine, l'homoserine, ou la valine a l'aide d'un micro-organisme a expression d'isocitrate lyase et/ou de malate synthase amelioree

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087139A2 (fr) 2010-01-15 2011-07-21 Ajinomoto Co.,Inc. Bactérie de la famille enterobacteriaceae produisant de l'acide l-aspartique ou des métabolites dérivés de l'acide l-aspartique et procédé de fabrication d'acide l-aspartique ou de métabolites dérivés de l'acide l-aspartique
WO2011087139A3 (fr) * 2010-01-15 2011-10-06 Ajinomoto Co.,Inc. Bactérie de la famille enterobacteriaceae produisant de l'acide l-aspartique ou des métabolites dérivés de l'acide l-aspartique et procédé de fabrication d'acide l-aspartique ou de métabolites dérivés de l'acide l-aspartique
US9051591B2 (en) 2010-01-15 2015-06-09 Ajinomoto Co., Inc. Bacterium of enterobacteriaceae family producing L-aspartic acid or L-aspartic acid-derived metabolites and a method for producing L-aspartic acid or L-aspartic acid-derived metabolites
WO2015199396A1 (fr) * 2014-06-23 2015-12-30 씨제이제일제당 주식회사 Microorganisme produisant de l'o-acétyl homosérine et procédé de production d'o-acétyl homosérine à l'aide dudit microorganisme
KR20160000098A (ko) * 2014-06-23 2016-01-04 씨제이제일제당 (주) O-아세틸 호모세린을 생산하는 미생물 및 상기 미생물을 이용하여 o-아세틸 호모세린을 생산하는 방법
KR101641770B1 (ko) * 2014-06-23 2016-07-22 씨제이제일제당 (주) O-아세틸 호모세린을 생산하는 미생물 및 상기 미생물을 이용하여 o-아세틸 호모세린을 생산하는 방법
US10465217B2 (en) 2014-06-23 2019-11-05 Cj Cheiljedang Corporation Microorganism producing O-acetyl homoserine and the method of producing O-acetyl homoserine using the same
US10815509B2 (en) 2014-06-23 2020-10-27 Cj Cheiljedang Corporation Microorganism producing O-acetyl homoserine and the method of producing O-acetyl homoserine using the same
CN108866028A (zh) * 2017-05-09 2018-11-23 中国科学院微生物研究所 一种氨基裂解酶突变体蛋白及其编码基因与应用
CN108866028B (zh) * 2017-05-09 2020-04-10 中国科学院微生物研究所 一种氨基裂解酶突变体蛋白及其编码基因与应用
WO2021060438A1 (fr) 2019-09-25 2021-04-01 Ajinomoto Co., Inc. Procédé de production d'acides l-aminés par fermentation bactérienne
JP2023506053A (ja) * 2020-01-30 2023-02-14 シージェイ チェイルジェダング コーポレイション クエン酸シンターゼの活性が弱化した新規な変異型ポリペプチド及びそれを用いたｌ－アミノ酸生産方法

Also Published As

Publication number Publication date
RU2411289C2 (ru) 2011-02-10
RU2008138615A (ru) 2010-04-10

Similar Documents

Publication Publication Date Title
JP4665451B2 (ja) Ｌ−リジンまたはｌ−スレオニンの製造法
US7186531B2 (en) L-threonine producing bacterium belonging to the genus Escherichia and method for producing L-threonine
JP5846122B2 (ja) Ｌ−アスパラギン酸又はｌ−アスパラギン酸より誘導される代謝産物を生産する腸内細菌科の細菌、及びｌ−アスパラギン酸又はｌ−アスパラギン酸より誘導される代謝産物の製造方法
KR100976072B1 (ko) 에스세리키아속 세균을 사용하는 ｌ-트레오닌의 제조방법
KR101537508B1 (ko) Ｌ-리신의 제조법
US20050181488A1 (en) Method for producing L-threonine using bacteria belonging to the genus Escherichia
EP2089528B1 (fr) Procede utilise pour produire un l-aminoacide au moyen d'une bacterie appartenant au genre escherichia ayant expression attenuee de l'un ou l'autre des genes cynt, cyns, cynx ou cynr ou d'une combinaison desdits genes
WO2007037460A1 (fr) Bacterie produisant un amino acide l et procede de production d'amino acides l
EP2185683B1 (fr) Procédé de production de l-threonine au moyen d'une bactérie de la famille des enterobacteriaceae, ayant une expression atténuée du gène yahn
WO2010038905A1 (fr) Bactérie appartenant au genre pantoea produisant un acide l-aspartique ou des métabolites dérivés de l'acide l-aspartique et procédé de production d'acide l-aspartique ou de métabolites dérivés de l'acide l-aspartique
EP1838850B1 (fr) Procede de production d'acide l-amine au moyen d'une bacterie de la famille des enterobacteriaceae possedant un trajet de biosynthese de glycogene interrompu
CA2549298C (fr) Bacterie productrice de l-threonine appartenant a l'espece escherichia et procede de production de l-threonine
WO2021060337A1 (fr) Procédé de production d'acide 2-méthyl-butyrique par fermentation bactérienne
JP5504608B2 (ja) １，５−ペンタンジアミンの製造方法
MXPA06006334A (en) L-threonine producing bacterium belonging to the genus escherichia and method for producing l-threonine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09788093

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09788093

Country of ref document: EP

Kind code of ref document: A1